# Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

> **NCT01024231** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 127 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** BMS-936558 (MDX1106-04)
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT01024231
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12-14
- **Primary completion:** 2014-02-04
- **Final completion:** 2019-04-01
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2021-03-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01024231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01024231, "Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01024231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*